Coronavirus Disease 2019

Update on Coronavirus Disease 2019 Outcomes and Vaccine Efficacy in Patients With Immune-Mediated Inflammatory Disease

Jeffrey A. Sparks; Zachary S. Wallace; Philip C. Robinson


Curr Opin Rheumatol. 2021;33(5):412-418. 

In This Article


Patients with immune-mediated inflammatory disease have offered important insight into the COVID-19 disease course. Findings have generally suggested either no or modest differences in severity of COVID-19, which provides reassurance to patients and clinicians. However, subgroups of patients may be susceptible to poor outcomes, in particular, patients on rituximab as well as those requiring glucocorticoids because of elevated underlying disease activity. Some evidence suggests that immunocompromised patients may have prolonged viral infection that may result in viral evolution resulting in SARS-CoV-2 variants. COVID-19 vaccinations offer the possibility to protect immune-mediated inflammatory disease patients. However, the underlying altered immunity and immunomodulator use may blunt vaccine response.